Friday, November 13, 2026

Repligen Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 14, 2020

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Repligen Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Repligen Corporation

43.1% sales growth and 4.04% return on equity

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Repligen Corporation sales growth this year is anticipated to be 30.1% and 28.6% for next year.

Year-on-year quarterly revenue growth grew by 35.4%, now sitting on 327.09M for the twelve trailing months.

Repligen Corporation's sales growth for the next quarter is 43.1%. The company's growth estimates for the ongoing quarter and the next is 55% and 9.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.04%.

Repligen Corporation's Stock Top and Bottom Yearly Value

Repligen Corporation's stock is valued at $188.33 at 19:57 EST, way below its 52-week high of $212.55 and way higher than its 52-week low of $78.41.

Repligen Corporation's Moving Average

Repligen Corporation's worth is higher than its 50-day moving average of $184.54 and way above its 200-day moving average of $150.77.

2. Pembina Pipeline Corp. Ordinary Shares

69.5% sales growth and 6.52% return on equity

Pembina Pipeline Corporation provides transportation and midstream services for the energy industry in North America.

Pembina Pipeline Corp. Ordinary Shares sales growth this year is anticipated to be 52% and 2% for next year.

Year-on-year quarterly revenue growth declined by 7.7%, now sitting on N/A for the twelve trailing months.

Pembina Pipeline Corp. Ordinary Shares's sales growth for the next quarter is 69.5%. The company's growth estimates for the ongoing quarter and the next is 12.8% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.52%.

Pembina Pipeline Corp. Ordinary Shares's Stock Top and Bottom Yearly Value

Pembina Pipeline Corp. Ordinary Shares's stock is valued at $27.10 at 19:57 EST, way below its 52-week high of $40.65 and way above its 52-week low of $10.58.

Pembina Pipeline Corp. Ordinary Shares's Moving Average

Pembina Pipeline Corp. Ordinary Shares's worth is way above its 50-day moving average of $23.68 and way higher than its 200-day moving average of $24.25.

3. XP Inc.

47% sales growth and 32.64% return on equity

XP Inc. operates technology-driven financial services platform that provides financial products and services in Brazil.

XP Inc. sales growth this year is anticipated to be 66.1% and 37.6% for next year.

Year-on-year quarterly revenue growth grew by 54.9%, now sitting on N/A for the twelve trailing months.

XP Inc.'s sales growth for the next quarter is 47%. The company's growth estimates for the current quarter and the next is 33.3% and 42.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.64%.

XP Inc.'s Stock Top and Bottom Yearly Value

XP Inc.'s stock is valued at $37.93 at 19:57 EST, way below its 52-week high of $52.94 and way higher than its 52-week low of $15.50.

XP Inc.'s Moving Average

XP Inc.'s worth is under its 50-day moving average of $41.00 and way under its 200-day moving average of $43.08.

4. Boston Beer Company, Inc.

40.7% sales growth and 21.12% return on equity

The Boston Beer Company, Inc. produces and sells alcohol beverages primarily in the United States.

Boston Beer Company, Inc. sales growth this year is anticipated to be 38.8% and 37.2% for next year.

Year-on-year quarterly revenue growth grew by 30.2%, now sitting on 1.58B for the twelve trailing months.

Boston Beer Company, Inc.'s sales growth for the next quarter is 40.7%. The company's growth estimates for the ongoing quarter and the next is 97% and 83.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.12%.

Boston Beer Company, Inc.'s Stock Top and Bottom Yearly Value

Boston Beer Company, Inc.'s stock is valued at $940.17 at 19:57 EST, way under its 52-week high of $1,092.80 and way higher than its 52-week low of $290.02.

Boston Beer Company, Inc.'s Moving Average

Boston Beer Company, Inc.'s value is under its 50-day moving average of $969.65 and way higher than its 200-day moving average of $802.16.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com